NNOX — Nano-X Imaging Ltd.

Nano-X Imaging (NNOX) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• GAAP Net Loss: $33.4 million, up from $14.1 million in Q4 2024, primarily due to a $17.5 million impairment of long-lived assets related to restructuring.
• Revenue: $3.7 million, a 23% increase from $3.0 million in Q4 2024, driven by growth in teleradiology services and the consolidation of Nanox Health IT.
• Gross Loss: $3.6 million (GAAP), compared to $2.9 million in Q4 2024. Non-GAAP gross loss was $1.2 million, with a gross loss margin of 32%.
• Teleradiology Revenue: $3.1 million, up from $2.8 million in the prior year, with a gross profit margin of approximately 27%.
• Cash Position: $60 million as of December 31, 2025, up from $55.5 million at the end of Q3 2025.

2. Strategic Updates and Business Highlights

• Partnerships: Entered a significant agreement with Howard Technology Solutions to deploy 300 Nanox.ARC systems over three years, with 60 expected in the first year. Additional agreements could lead to approximately 400 systems globally.
• Operational Restructuring: Implemented a restructuring plan to shift manufacturing from in-house to outsourced models, aiming to reduce costs and improve efficiency.
• Acquisition: Completed the acquisition of VasoHealthcare IT, enhancing capabilities in health IT and expected to contribute to revenue immediately.
• Regulatory Progress: Achieved TAP2D clearance in the U.S. and updated AMAR approval in Israel, which may expand the addressable market.

3. Forward Guidance and Outlook

• 2026 Revenue Target: Aiming for $35 million, with expectations for revenue growth to accelerate in the second half of the year as deployment ramps up.
• Deployment Timeline: Anticipated gradual increase in system activations, with a focus on onboarding new partners and expanding market presence.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The significant increase in net loss raises concerns about financial sustainability amidst ongoing restructuring costs.
• Impairment Issues: The $17.5 million impairment reflects challenges in the South Korean manufacturing facility, which may impact future operational efficiency.
• Pace of Deployment: The company acknowledged that external factors, including regulatory processes and construction timelines, are slowing down deployment speed, which could affect revenue realization.
• Market Competition: The introduction of innovative technology in healthcare remains complex, requiring alignment across various stakeholders, which could pose risks to timely market penetration.

5. Notable Q&A Insights

• Sales Organization: The U.S. sales team consists of direct salespeople and clinical education specialists focused on training and awareness-building at installed sites.
• Restructuring Costs: Minor additional restructuring costs are expected in 2026, primarily cash-based, but not material.
• Revenue Cadence: Most revenue growth is anticipated in the latter half of 2026, with Q1 expected to show limited growth.
• Teleradiology Growth: While specific segment guidance was avoided, low double-digit growth in teleradiology services was suggested as a reasonable expectation.
• Spending Trends: Increased spending in Q4 was attributed to seasonal factors and acquisition-related costs, with expectations for a decline in future quarters as restructuring takes effect.

This summary encapsulates the key aspects of Nano-X Imaging's Q4 2025 earnings call, highlighting both the progress made and the challenges faced by the company as it navigates its growth strategy.